Analysts have downgraded their earnings per share estimates for Sinopharm Group, indicating a decline in sentiment. They also suggest that Sinopharm may underperform compared to the wider industry, but the consensus price target remains steady.
Sinopharm Group's declining ROCE trend is concerning. Increased capital investment without matching sales suggests long-term plays. High current liabilities to total assets ratio introduces risk. These trends indicate Sinopharm may not be a multi-bagger.
$Hang Seng Index(800000.HK)$plunge deepened unceasingly after midday. It once stumbled 620 pts or 3.9% to bottom at 15,245, hitting an over-14-month low; last at 15,320, down 545 pts or 3.4%, with a total turnover of $88.5 billion. Pharmaceuticals were sold off.$REMEGEN-B(09995.HK)$once collapsed 27.5% to $22.8; last at $24.9, down 21%. $CLOVER BIO-B(02197.HK)$nosedived 9.6% to $0.47, hitting record low.$維亜生物科技(01873.HK)$...
Sinopharm Group's low P/E ratio is due to investors' limited growth expectations, leading to a reduced stock price. The poor earnings outlook from analysts also contributes to its low P/E. These conditions may continue to hinder the share price.
Sinopharm Group is currently undervalued and it might be a good time to accumulate more holdings in the stock. The positive outlook on the horizon of the company's future seems not to be fully factored into the current share price.
The declining trend in Sinopharm Group's ROCE and the stock's 42% fall in the last five years doesn't inspire investor confidence. The article doesn't consider Sinopharm Group as a potential multi-bagger based on the present analysis.
$国薬(01099.HK)$ Sinopharm is principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is en...
国薬に関するコメント
Pharmaceuticals were sold off. $REMEGEN-B(09995.HK)$ once collapsed 27.5% to $22.8; last at $24.9, down 21%.
$CLOVER BIO-B(02197.HK)$ nosedived 9.6% to $0.47, hitting record low. $維亜生物科技(01873.HK)$ ...
$AMCエンターテインメント HD A(AMC.US)$ $国薬(01099.HK)$ $Kweichow Moutai(600519.SH)$ $アリババ・グループ・ホールディング(BABA.US)$ $テンセント(00700.HK)$ $JD.COM(京東商城)(JD.US)$ $Sheng Siong(OV8.SG)$ $UOB(U11.SG)$ $Singtel(Z74.SG)$ $バイオエヌテック(BNTX.US)$ $シー(SE.US)$
Sinopharm is principally engaged in pharmaceutical and medical devices distribution business. The Company operates its business through four segments. Pharmaceutical Distribution segment is engaged in the distribution of pharmaceutical products to hospitals, other distributors, retail pharmacy stores and clinics. Medical Devices segment is engaged in the distribution of medical devices, as well as provides installation and maintenance services. Retail Pharmacy segment is en...
$微創医療科学(00853.HK)$ $山東威高(01066.HK)$ $石薬集団(01093.HK)$ $国薬(01099.HK)$ $鳳凰医療(01515.HK)$ $康臣薬業(01681.HK)$ $春立医療(01858.HK)$ $環球医療(02666.HK)$ $復宏漢霖(02696.HK)$ $B-Soft Co.,Ltd.(300451.SZ)$ $Guangxi LiuYao Group(603368.SH)$ $百済神州(06160.HK)$
$国薬(01099.HK)$
まだコメントはありません